<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385124</url>
  </required_header>
  <id_info>
    <org_study_id>6276</org_study_id>
    <nct_id>NCT01385124</nct_id>
  </id_info>
  <brief_title>Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing
      allogeneic hematopoietic cell transplantation. Despite prophylactic measures, the incidence
      of acute GVHD is estimated at 40-60% among patients receiving transplant from HLA-identical
      sibling donors, and may even reach 75% in patients receiving HLA-matched unrelated
      transplants. More effective prevention and treatment strategies are needed.

      The immunomodulatory and anti-inflammatory properties of Cannabinoids have been shown in
      animal models of various inflammatory diseases including multiple sclerosis, inflammatory
      bowel disease and rheumatoid arthritis.

      Cannabidiol is a major non-psychoactive cannabinoid, which has potent anti-inflammatory and
      immunosuppressive effects.

      As such, it may reduce the incidence and severity of GVHD after allogeneic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall percentage of patients with acute GVHD at day 100 post-transplant</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with grade III/IV acute GVHD at day 100 post-transplant</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Oral Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Cannabidiol</intervention_name>
    <description>Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.</description>
    <arm_group_label>Oral Cannabidiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing allogeneic stem cell transplantation.

          2. No previous history of psychosis. -

        Exclusion Criteria:

          1. Previous history of psychosis.

          2. Consumption of cannabis during the last 2 moths before transplantation. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Yeshurun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davidoff cancer center, Beilinson hospital, Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Yeshurun, MD</last_name>
    <phone>972-9378127</phone>
    <email>moshey@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ron Ram, MD</last_name>
    <phone>972-9378116</phone>
    <email>RonRa@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Davidoff Cancer Center, Beilin hospital, Rabin medical center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Moshe Yeshurun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic transplantation</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

